Michael P. Cooke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Cooke has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Albert E. Parker
Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121
2 shared publicationsSue E. Sutton
Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121
2 shared publicationsAlex Cortez
The Genomics Institute of Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
1 shared publication- Amanda L. Vegoe
Center for Immunology, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
1 shared publication Andrew T. Miller
The Genomics Institute of Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
1 shared publication- Andrew T. Miller
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publication
Latest Publications
- 19 November 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (263) , 263ra160
Rational design of small molecules as vaccine adjuvants
Small-molecule immune potentiators can be engineered to be potent adjuvants with localized innate immune activation and short in vivo residence times.
- 19 November 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (263) , 263ra160
Rational design of small molecules as vaccine adjuvants
Small-molecule immune potentiators can be engineered to be potent adjuvants with localized innate immune activation and short in vivo residence times.
- Open Access
- 24 December 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 210 (1) , 23-30
The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain
B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells. We report, using N-ethyl-N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development. The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell–dependent antibody responses. Additionally, chompB mice have decreases in myeloid dendritic cells (DCs). The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development. Proteomic analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival. Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.
- 24 December 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 210 (1) , 23-30
Open AccessThe intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain
B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells. We report, using N-ethyl-N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development. The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell–dependent antibody responses. Additionally, chompB mice have decreases in myeloid dendritic cells (DCs). The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development. Proteomic analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival. Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.
- 30 March 2011
- Published by Elsevier in Immunology Letters
- Vol. 135 (1-2) , 74-77
Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways
- 30 March 2011
- Published by Elsevier in Immunology Letters
- Vol. 135 (1-2) , 74-77
Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways
- Top Cited Papers
- 10 September 2010
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 329 (5997) , 1345-1348
Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Stem Cell Expansion: The ability to expand hematopoietic stem cells (HSCs) during ex-vivo culture has been an important goal for over 20 years. Using a high-throughput chemical screen, Boitano et al. (p. 1345 , published online 5 August; see the Perspective by Sauvageau and Humphries ) found that a purine derivative, StemRegenin1 (SR1), promoted the expansion of human HSCs. Treatment of HSCs with SR1 (which blocked the activity of the aryl hydrocarbon receptor) led to the expansion of CD34 + cells and a 12 to 17-fold increase in the number of HSCs that engraft immune deficient mice.
- 10 September 2010
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 329 (5997) , 1345-1348
Top Cited PapersAryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Stem Cell Expansion: The ability to expand hematopoietic stem cells (HSCs) during ex-vivo culture has been an important goal for over 20 years. Using a high-throughput chemical screen, Boitano et al. (p. 1345 , published online 5 August; see the Perspective by Sauvageau and Humphries ) found that a purine derivative, StemRegenin1 (SR1), promoted the expansion of human HSCs. Treatment of HSCs with SR1 (which blocked the activity of the aryl hydrocarbon receptor) led to the expansion of CD34 + cells and a 12 to 17-fold increase in the number of HSCs that engraft immune deficient mice.